Investors must take note of Caribou Biosciences Inc’s (CRBU) performance last week, which was 17.33%.

Caribou Biosciences Inc (NASDAQ: CRBU) kicked off on Monday, up 8.22% from the previous trading day, before settling in for the closing price of $2.19. Over the past 52 weeks, CRBU has traded in a range of $1.50-$8.33.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 71.11% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -20.17%. With a float of $79.16 million, this company’s outstanding shares have now reached $90.55 million.

In an organization with 158 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.15%, operating margin of -1439.5%, and the pretax margin is -1289.12%.

Caribou Biosciences Inc (CRBU) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Caribou Biosciences Inc is 12.70%, while institutional ownership is 58.63%.

Caribou Biosciences Inc (CRBU) Latest Financial update

In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.41 earnings per share (EPS), lower than consensus estimate (set at -0.35) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -20.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.50% during the next five years compared to -37.16% drop over the previous five years of trading.

Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators

Take a look at Caribou Biosciences Inc’s (CRBU) current performance indicators. Last quarter, stock had a quick ratio of 7.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.63.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.84 in one year’s time.

Technical Analysis of Caribou Biosciences Inc (CRBU)

Let’s dig in a bit further. During the last 5-days, its volume was 1.87 million. That was better than the volume of 1.71 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 56.75%. Additionally, its Average True Range was 0.21.

During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 54.03%, which indicates a significant decrease from 57.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.21% in the past 14 days, which was higher than the 86.82% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.05, while its 200-day Moving Average is $3.05. However, in the short run, Caribou Biosciences Inc’s stock first resistance to watch stands at $2.44. Second resistance stands at $2.52. The third major resistance level sits at $2.65. If the price goes on to break the first support level at $2.23, it is likely to go to the next support level at $2.10. The third support level lies at $2.02 if the price breaches the second support level.

Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats

The company with the Market Capitalisation of 213.63 million has total of 90,553K Shares Outstanding. Its annual sales at the moment are 34,480 K in contrast with the sum of -102,070 K annual income. Company’s last quarter sales were recorded 2,020 K and last quarter income was -34,680 K.